-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, T0iYMyUlc1CeCqfUEfkG1u7GHjWswtPltjpdnDE708iyNZ7ykED7NFg2SM+zK8jV Jl/+/TTz613S5vBpY0uy2g== 0001016504-03-000029.txt : 20031117 0001016504-03-000029.hdr.sgml : 20031117 20031117102503 ACCESSION NUMBER: 0001016504-03-000029 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20031114 ITEM INFORMATION: Financial statements and exhibits ITEM INFORMATION: Regulation FD Disclosure FILED AS OF DATE: 20031117 FILER: COMPANY DATA: COMPANY CONFORMED NAME: INTEGRATED BIOPHARMA INC CENTRAL INDEX KEY: 0001016504 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133035216 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-31668 FILM NUMBER: 031006851 BUSINESS ADDRESS: STREET 1: 201 ROUTE 22 CITY: HILLSIDE STATE: NJ ZIP: 07205 BUSINESS PHONE: 9739260816 MAIL ADDRESS: STREET 1: 201 ROUTE 22 CITY: HILLSIDE STATE: NJ ZIP: 07205 FORMER COMPANY: FORMER CONFORMED NAME: INTEGRATED HEALTH TECHNOLOGIES INC DATE OF NAME CHANGE: 20020912 FORMER COMPANY: FORMER CONFORMED NAME: CHEM INTERNATIONAL INC DATE OF NAME CHANGE: 19960716 8-K 1 inb8knov14_2003.txt INTEGRATED BIOPHARMA, INC. - NOVEMBER 14, 2003 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ------------- FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 14, 2003 INTEGRATED BIOPHARMA, INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-28876 22-2407475 (State or Other Jurisdiction (Commission (IRS Employer of Incorporation) File Number) Identification No.) 225 Long Ave., Hillside, New Jersey 07205 (Address of Principal Executive Offices) (Zip Code) Registrant's telephone number, including area code (973) 926-0816 NOT APPLICABLE (Former Name or Former Address, if Changed Since Last Report) ITEM 7. Financial Statements and Exhibits. (c) Exhibits Exhibit Number Description 99.1 Press Release of Integrated BioPharma, Inc. dated November 14, 2003 reporting results for the quarter ended September 30, 2003. ITEM 9. Regulation FD Disclosure. In accordance with SEC Release No. 33-8216, the following information, required to be furnished under "Item 12. Results of Operations and Financial Condition," is furnished under "Item 9. Regulation FD Disclosure". On November 14, 2003 the Company issued a press release reporting results for the quarter ended September 30, 2003, the text of which is attached hereto as Exhibit 99.1 and incorporated herein in its entirety by reference. The statements in this Current Report on Form 8-K, including the exhibits, contain forward-looking statements and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risk and uncertainties which may affect the Registrant's business prospects, including economic, competitive, governmental, technological and other factors discussed in filings with the Securities and Exchange Commission. 2 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. INTEGRATED BIOPHARMA, INC. November 17, 2003 By: /s/Eric Friedman -------------------- Name: Eric Friedman Title: Vice President 3 EXHIBIT INDEX Exhibit Number Description 99.1 Press Release of Integrated BioPharma, Inc. dated November 14, 2003 reporting results for the quarter ended September 30, 2003. 4 EX-99 2 exhibit99_1.txt INTEGRATED BIOPHARMA - 11/14/03 PRESS RELEASE Exhibit 99.1 FOR IMMEDIATE RELEASE Contact: Jamie E. Levey November 14, 2003 Investor Relations (888) 319-6962 Integrated BioPharma Reports First Quarter Financial Results Hillside, N.J., November 14, 2003--Integrated BioPharma, Inc. (AMEX:INB) announced its financial results for the first quarter ended September 30, 2003. First quarter revenues increased approximately 3% to $4,980,006 from $4,848,190 for the same period a year ago. Net operating (loss) for the quarter was $(756,295) or $(0.08) per share on 10,306,335 shares outstanding compared to operating income of $186,510 or $0.03 per share on 7,070,783 shares outstanding for the comparable quarter of last year. The decrease in net income is mainly attributable to one-time only transactional expenses related to the recent acquisitions and to the inclusion of start up operational expenses at Paxis Pharmaceuticals, Inc. in preparation for the production of Paclitaxel. For the Three Months Ended September 30, September 30, 2003 2002 ---- ---- Total Revenue $ 4,980,006 $ 4,848,190 ------------- ------------- Pretax Operating (Loss) Income (779,470) 311,678 Provision for Income Taxes (23,175) 125,168 ------------- ------------- Net (Loss) Income $ (756,295) $ 186,510 ============= ============= Diluted EPS $ (0.08) $ 0.03 ============= ============= Average Common Shares Outstanding-fully diluted 10,306,335 7,170,783 ============= ============= Since the close of the quarter ended September 30, 2003, the Company has acquired three new products having annual sales of approximately $3 million. The Company has begun sales of these products. Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects, and internal issues in the sponsoring client. Further information on potential risk factors that could affect the company's financial results can be found in the company's Reports filed with the Securities and Exchange Commission. -----END PRIVACY-ENHANCED MESSAGE-----